LLY
Eli Lilly and Company
LLY has the edge over STVN overall, supported by stronger fundamentals and lower modeled downside.
STVN
Stevanato Group S.p.A.
STVN's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
STVN's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 27x | $14.36 | — |
| Cheap | 31x | $16.55 | +15% |
| Fair | 39x | $20.56 | +43% |
| Expensive | 49x | $25.80 | +80% |
Historical ranges are pointers, not guarantees.
STVN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over STVN on the outlook, with more favorable revenue expectations.
STVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect STVN's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STVN on earnings, with more consistent year-over-year improvement.
STVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.53 | -5.4% |
| Q1 2026 | $0.57 | +9.6% |
| Q4 2025 | $0.57 | +16% |
| Q3 2025 | $0.58 | +23% |
| Q2 2025 | $0.56 | +7.7% |
| Q1 2025 | $0.52 | -10% |
| Q4 2024 | $0.49 | -21% |
| Q3 2024 | $0.47 | -24% |
STVN earned $0.53 per share over the past year, down 5.4% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STVN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STVN on profitability, with a higher operating margin.
STVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $335.5M | +7.8% |
| Q1 2026 | $303.9M | +6.6% |
| Q4 2025 | $381.3M | +3.8% |
| Q3 2025 | $336.8M | +9.1% |
| Q2 2025 | $311.1M | +7.9% |
| Q1 2025 | $285.1M | +8.7% |
| Q4 2024 | $367.3M | +3.1% |
| Q3 2024 | $308.7M | +2.4% |
STVN's revenue has grown year over year for nine quarters in a row: $335M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -1.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 19% | -1 points |
| Q3 2025 | 17% | +2.6 points |
| Q2 2025 | 15% | +4 points |
| Q1 2025 | 14% | +2.8 points |
| Q4 2024 | 20% | +0.3 points |
| Q3 2024 | 15% | -4.1 points |
STVN's operating margin was 13% last quarter, down 1.8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
STVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$37.6M | -$20.6M |
| Q1 2026 | $5.3M | -83% |
| Q4 2025 | $5.2M | +$55.4M |
| Q3 2025 | -$1.3M | +$121.2M |
| Q2 2025 | -$17.1M | +$34.6M |
| Q1 2025 | $31.2M | +$65.7M |
| Q4 2024 | -$50.3M | +$35.2M |
| Q3 2024 | -$122.5M | +$166.1M |
STVN has burned cash in most quarters: −$28M over the past year, against −$159M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -21.1K shares |
| 1 year | 0% | +77K shares |
| 3 years | +2.9% | +7.6M shares |
| 5 years | -9.1% | -27.4M shares |
| Available history | -7.4% | -21.8M shares |
STVN has 273M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
STVN hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.0x | Healthy |
| Q1 2025 | 1.0x | Healthy |
| Q4 2024 | 1.1x | Healthy |
| Q3 2024 | 1.0x | Healthy |
STVN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 17.5 | Oversold |
STVN's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STVN PE vs Healthcare Sector
| Metric | STVN | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 4.2% above |
| PE % | 6 | 38 | 32 pts below |
STVN has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STVN on trend strength, trading above more of its moving averages.
STVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.3 | 22% below |
| 20 week MA | $19.6 | 27% below |
| 50 week MA | $18.2 | 21% below |
| 100 week MA | $20.7 | 30% below |
| 200 week MA | $23.1 | 38% below |
STVN is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STVN on returns for 2026, with the stronger performance.
STVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.7 | $23.3 | +19% |
| 2022 | $23.3 | $17.9 | -23% |
| 2023 | $17.9 | $27.3 | +53% |
| 2024 | $27.3 | $21.6 | -21% |
| 2025 | $21.6 | $20.7 | -4.2% |
| 2026 YTD | $20.7 | $14.4 | -31% |
STVN has finished lower in three of the last five years. It's down 31% so far in 2026.